# **Special Issue**

# Mechanism of Carbapenem Resistance in Enterobacteriaceae, Acinetobacter and Pseudomonas aeruginosa

# Message from the Guest Editor

Infections caused by carbapenem-resistant Gramnegative pathogens, i.e., carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), and MDR Pseudomonas aeruginosa are listed by the World Health Organization as pathogens of critical priority. Infections caused by such pathogens are difficult to treat, even if we consider the beta-lactam/beta lactamase inhibitor (BL/BLI) drugs and cefiderocol, which were recently introduced into medical practice. Manuscripts are invited concerning the following areas of interest:

- In vitro diagnostic tools for the phenotypic detection of carbapenemase enzymes and carbapenem resistance in *Enterobacteriaceae*, *Acinetobacter spp.*, and *Pseudomonas aeruginosa*;
- Molecular epidemiology of CRE, CRAB, and carbapenem-resistant Pseudomonas aeruginosa;
- Evaluation of the treatment efficacy of the new betalactam/beta lactamase inhibitors or cefiderocol in infections caused by CRE, CRAb and MDR aeruginosa in relation to their resistance mechanisms.

#### **Guest Editor**

Dr. Ágnes Pál-Sonnevend

Department of Medical Microbiology and Immunology, University of Pécs Medical School, 7624 Pecs, Hungary

#### **Deadline for manuscript submissions**

31 May 2026



an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



mdpi.com/si/115735

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



# **About the Journal**

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

#### Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

#### **Author Benefits**

## **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

